We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Quest Diagnostics (DGX - Free Report) . Shares have lost about 5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Quest Diagnostics due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Quest Diagnostics Incorporated before we dive into how investors and analysts have reacted as of late.
Quest Diagnostics' first-quarter 2026 adjusted earnings per share of $2.50 beat the Zacks Consensus Estimate by 5.45%. The metric also exceeded the year-ago adjusted figure by 13.1%.
Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjusted figures. GAAP earnings came in at $2.24 per share, up 15.5% from last year’s comparable figure.
DGX’s Revenues in Detail
Revenues reported in the first quarter rose 9.2% year over year to $2.90 billion. The metric surpassed the Zacks Consensus Estimate by 3.14%.
Diagnostic Information Services revenues in the quarter were up 9.4% on a year-over-year basis to $2.83 billion. Our model forecast was $2.74 billion.
Volumes (measured by the number of requisitions) were up 10.9% year over year in the first quarter. Revenue per requisition dropped 1.3% year over year.
DGX’s Q1 Margin Performance
The cost of services during the reported quarter was $1.95 billion, up 9.2% year over year. The gross profit came in at $942 million, rising 9.2% year over year. The gross margin of 32.5% was unchanged from the year-ago figure.
SG&A expenses were $504 million in the quarter under review, increasing 5.9% from the first quarter of 2025. The adjusted operating margin of 15.1% represented a 54 bps expansion year over year.
DGX’s Financial Position
Quest Diagnostics exited the first quarter of 2026 with cash and cash equivalents of $393 million compared with $420 million at the end of 2025.
The cumulative net cash provided by operating activities at the end of the first quarter of 2026 was $278 million compared with $314 million a year ago.
DGX’s 2026 Guidance
Quest Diagnostics provided an updated full-year 2026 outlook. Revenues are now expected in the range of $11.78-$11.90 billion (earlier $11.70-$11.82 billion), which indicates a year-over-year increase of 6.8%-7.8%. The Zacks Consensus Estimate is pegged at $11.76 billion.
Adjusted earnings per share is expected between $10.63 and $10.83 (previously $10.50-$10.70). The Zacks Consensus Estimate for the metric is pegged at $10.60.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
Currently, Quest Diagnostics has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of B on the value side, putting it in the second quintile for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Quest Diagnostics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report?
A month has gone by since the last earnings report for Quest Diagnostics (DGX - Free Report) . Shares have lost about 5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Quest Diagnostics due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Quest Diagnostics Incorporated before we dive into how investors and analysts have reacted as of late.
Quest Diagnostics Tops Q1 Earnings & Revenue Estimates
Quest Diagnostics' first-quarter 2026 adjusted earnings per share of $2.50 beat the Zacks Consensus Estimate by 5.45%. The metric also exceeded the year-ago adjusted figure by 13.1%.
Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjusted figures. GAAP earnings came in at $2.24 per share, up 15.5% from last year’s comparable figure.
DGX’s Revenues in Detail
Revenues reported in the first quarter rose 9.2% year over year to $2.90 billion. The metric surpassed the Zacks Consensus Estimate by 3.14%.
Diagnostic Information Services revenues in the quarter were up 9.4% on a year-over-year basis to $2.83 billion. Our model forecast was $2.74 billion.
Volumes (measured by the number of requisitions) were up 10.9% year over year in the first quarter. Revenue per requisition dropped 1.3% year over year.
DGX’s Q1 Margin Performance
The cost of services during the reported quarter was $1.95 billion, up 9.2% year over year. The gross profit came in at $942 million, rising 9.2% year over year. The gross margin of 32.5% was unchanged from the year-ago figure.
SG&A expenses were $504 million in the quarter under review, increasing 5.9% from the first quarter of 2025. The adjusted operating margin of 15.1% represented a 54 bps expansion year over year.
DGX’s Financial Position
Quest Diagnostics exited the first quarter of 2026 with cash and cash equivalents of $393 million compared with $420 million at the end of 2025.
The cumulative net cash provided by operating activities at the end of the first quarter of 2026 was $278 million compared with $314 million a year ago.
DGX’s 2026 Guidance
Quest Diagnostics provided an updated full-year 2026 outlook. Revenues are now expected in the range of $11.78-$11.90 billion (earlier $11.70-$11.82 billion), which indicates a year-over-year increase of 6.8%-7.8%. The Zacks Consensus Estimate is pegged at $11.76 billion.
Adjusted earnings per share is expected between $10.63 and $10.83 (previously $10.50-$10.70). The Zacks Consensus Estimate for the metric is pegged at $10.60.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
VGM Scores
Currently, Quest Diagnostics has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of B on the value side, putting it in the second quintile for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Quest Diagnostics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.